BR0310068A - Uso de um ou mais de um composto, combinação, e, composição farmacêutica - Google Patents

Uso de um ou mais de um composto, combinação, e, composição farmacêutica

Info

Publication number
BR0310068A
BR0310068A BR0310068-5A BR0310068A BR0310068A BR 0310068 A BR0310068 A BR 0310068A BR 0310068 A BR0310068 A BR 0310068A BR 0310068 A BR0310068 A BR 0310068A
Authority
BR
Brazil
Prior art keywords
compound
combination
pharmaceutical composition
formula
injury
Prior art date
Application number
BR0310068-5A
Other languages
English (en)
Inventor
Adam J Smolka
Charles E Hammond
Sandeep Gupta
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of BR0310068A publication Critical patent/BR0310068A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UM OU MAIS DE UM COMPOSTO, COMBINAçãO, E, COMPOSIçãO FARMACêUTICA". A inibição da bomba de próton gástrica em um mamífero é efetuada através do uso de um composto da fórmula (1): em que as variáveis possuem o significado dado na presente descrição. Um composto preferido é o composto da fórmula (2): Este tratamento melhora, diminui, trata ativamente, reverte ou previne qualquer ferida, dano ou lesões da mucosa gástrica, por exemplo lesões da mucosa gástrica e ulceração.
BR0310068-5A 2002-05-17 2003-05-16 Uso de um ou mais de um composto, combinação, e, composição farmacêutica BR0310068A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30892802P 2002-05-17 2002-05-17
EP02011081 2002-05-17
PCT/EP2003/005171 WO2003097041A1 (en) 2002-05-17 2003-05-16 Annelated pyrrole compounds as proton pump inhibitors for treating ulcer

Publications (1)

Publication Number Publication Date
BR0310068A true BR0310068A (pt) 2005-03-08

Family

ID=37725454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0310068-5A BR0310068A (pt) 2002-05-17 2003-05-16 Uso de um ou mais de um composto, combinação, e, composição farmacêutica

Country Status (15)

Country Link
EP (1) EP1505964B1 (pt)
JP (1) JP2006509720A (pt)
CN (1) CN1309383C (pt)
AU (1) AU2003232788B2 (pt)
BR (1) BR0310068A (pt)
CA (1) CA2484238A1 (pt)
DE (1) DE60317661T2 (pt)
ES (1) ES2297204T3 (pt)
MX (1) MXPA04011097A (pt)
NZ (1) NZ536444A (pt)
PT (1) PT1505964E (pt)
RU (1) RU2336872C2 (pt)
UA (1) UA77812C2 (pt)
WO (1) WO2003097041A1 (pt)
ZA (1) ZA200410123B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351035A1 (de) * 2003-10-31 2005-05-25 Merckle Gmbh Chemisch Pharmazeutische Fabrik Pharmazeutische Licofelone-Formulierung
KR101115857B1 (ko) * 2005-08-30 2012-04-12 다케다 야쿠힌 고교 가부시키가이샤 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-ｈ-피롤 유도체
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
ES2534772T3 (es) * 2008-10-31 2015-04-28 C-A-I-R Biosciences Gmbh Sal de colina y trometamina de licofelona
CN106957252B (zh) * 2014-11-19 2019-11-19 连云港恒运药业有限公司 一种质子泵抑制剂中间体及其制备方法
SG11202011685QA (en) 2018-05-25 2020-12-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4419246A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419247A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5852033A (en) * 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
KR100447918B1 (ko) * 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
WO2001005792A1 (de) * 1999-11-23 2001-01-25 Merckle Gmbh Antiinflammatorische oxo- und hydroxyderivate von pyrrolizinen und deren anwendung in der pharmazie
EP1142889A1 (en) * 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazole derivatives as anti-inflammatory/analgesic agents

Also Published As

Publication number Publication date
ES2297204T3 (es) 2008-05-01
EP1505964A1 (en) 2005-02-16
ZA200410123B (en) 2006-07-26
WO2003097041A1 (en) 2003-11-27
EP1505964B1 (en) 2007-11-21
RU2004136994A (ru) 2005-06-10
AU2003232788B2 (en) 2008-10-02
DE60317661T2 (de) 2008-10-30
RU2336872C2 (ru) 2008-10-27
JP2006509720A (ja) 2006-03-23
CN1652771A (zh) 2005-08-10
DE60317661D1 (de) 2008-01-03
AU2003232788A1 (en) 2003-12-02
CN1309383C (zh) 2007-04-11
UA77812C2 (en) 2007-01-15
PT1505964E (pt) 2008-02-28
NZ536444A (en) 2006-12-22
MXPA04011097A (es) 2005-02-14
CA2484238A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
PA8486001A1 (es) Composiciones de celecoxib
BR0317891A (pt) Tratamento de ferimentos de pele usando polienilfosfatidil colina e alcanolaminas
BR9814755A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos para a preparação de um composto, para inibir a secreção do ácido gástrico, para o tratamento de doenças inflamatórias gastrointestinais, e para o tratamento ou profilaxia de condições que envolvam infecção por helicobacter pylori da mucosa gástrica humana
DE69306545D1 (de) Tucaresol als Mittel zur Immunopotentierung
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
HRP20050516B1 (hr) N-alkil-4-metilenamino-3-hidroksi-2-piridoni kao antimikrobni lijekovi
BR0014060A (pt) Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica
CL2004000969A1 (es) Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados.
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
BR9814327A (pt) Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
BR0313630A (pt) Composição para aplicação tópica, sistema para o tratamento de caspa, métodos para o tratamento e/ou prevenção da caspa e da coceira do couro cabeludo e usos de uma combinação sinérgica
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
DE69822668D1 (de) Heterozyklische ether- und thioether-verbindungen, verwendbar zur steuerung von chemischer synaptischer transmission
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
PT1251846E (pt) Taxanos com carbonato c-4
BR0205812A (pt) Benzimidazois úteis no tratamento da disfunção sexual
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
BR0215067A (pt) Piridoquinoxalinas antivirais
BR0114697A (pt) Derivados em ponte de piperazina
ATE137969T1 (de) Benzimidazolverbindungen als antibiotika gegen campylobacter pylon
BR0212244A (pt) Uso de um ou mais do que um composto e seus isÈmeros ópticos, derivados e sais fisiologicamente aceitáveis, composição farmacêutica, e, método de tratamento ou de prevenção da degeneração ou da destruição de cartilagem articular e/ou de osso subcondral em uma ou mais articulações de um mamìfero

Legal Events

Date Code Title Description
B08E Application fees: requirement for complementation of annuity fee

Free format text: COMPLEMENTAR 6A ANUIDADE DE ACORDO COM TABELA VIGENTE REFERENTE A GUIA 220805238333 E COMPROVAR RECOLHIMENTO DA 3A E 7A ANUIDADES.

B08J Application fees: republication

Free format text: REFERENTE AO DESPACHO 8.5 DA RPI 2082 DE 30/11/2010. TEXTO CORRETO: COMPLEMENTAR A 6A ANUIDADE REFERENTE A GRU 220805238333 E COMPROVAR O RECOLHIMENTO DA 7A ANUIDADE.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AO NAO CUMPRIMENTO DAS EXIGENCIAS PUBLICADAS NA RPI 2082 DE 30/11/2010 E RPI 2090 DE 25/01/2011.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.